Rising sickle cell disease prevalence is driving the Adakveo Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Adakveo Market Across 2026–2030?

The historical period’s growth stemmed from several factors: the restricted availability of sickle cell disease treatments, the substantial impact of vaso-occlusive crises, the authorization of innovative biologic therapies, a heightened awareness of disease complications, and the increasing adoption by specialist hematology.

The projected growth during the forecast period is influenced by an expanding population of sickle cell patients, the broadening of access programs, a heightened emphasis on preventive treatments, increasing investments in orphan drugs, and better integration of clinical guidelines.

Significant trends expected in the forecast period encompass the increasing application of targeted therapies for sickle cell disease, an amplified focus on preventing vaso-occlusive crises, a wider acceptance of P-selectin inhibitors, the extension of disease-modifying treatments, and enhancements in the long-term management of rare blood disorders.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19955&type=smp

What Drivers Are Shaping The Future Growth Of The Adakveo Market?

The increasing prevalence of sickle cell disease is expected to propel the growth of the adakveo market going forward. Sickle cell disease (SCD) refers to a group of inherited blood disorders caused by the presence of abnormal hemoglobin, known as hemoglobin S, in red blood cells. The increasing prevalence of sickle cell disease can be attributed to factors such as higher birth rates in regions with endemic malaria, genetic inheritance patterns, and improved survival rates due to advances in medical care, which allow more individuals to live longer with the condition. Adakveo helps sickle cell disease patients by reducing the frequency of vaso-occlusive crises, which are painful episodes caused by the blockage of blood flow in small vessels, through its mechanism of action that selectively inhibits the adhesion of sickle cells to blood vessel walls, thereby improving blood flow and alleviating the symptoms of this debilitating condition. For instance, in July 2024, according to the Pennsylvania Bar Institute (PBI), a US-based organization, in 2021, approximately 7.74 million people had sickle cell disease (SCD). The number of newborns diagnosed annually is projected to increase from 275,000 in 2021 to over 400,000 by 2050. Therefore, the increasing prevalence of sickle cell disease is driving the adakveo market. A rise in healthcare expenditure is expected to boost the growth of the adakveo market going forward. Healthcare expenditure is attributed to the financial investment made by governments, private insurers, and individuals in the healthcare system to improve and expand medical services. Healthcare expenditure supports Adakveo by enabling greater investment in innovative treatments for sickle cell disease, improving patient access to this targeted therapy, which helps reduce the burden of vaso-occlusive crises and enhances the quality of life for patients, especially in regions with advanced healthcare systems and adequate funding for specialty drugs. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK grew by 5.6% from 2022 to 2023, a significant increase compared to the 0.9% growth in 2022. In 2023, the UK’s healthcare expenditure totaled approximately $317.63 billion (£292 billion). Thus, the rise in healthcare expenditure will drive the growth of the adakveo market.

What Segmentation Levels Are Considered In The Adakveo Market?

The adakveo market covered in this report is segmented –

1) By Indication: Sickle Cell Disease (Adults and Pediatric Patients), Vaso-Occlusive Crisis Prevention

2) By Route Of Administration: Intravenous Injection, Infusion Therapy, Oral

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End-User: Hospitals, Clinics, Ambulatory Care, Home Care

Which Leading Firms Are Contributing To The Growth Of The Adakveo Market?

Major companies operating in the adakveo market are Novartis AG

Read the full adakveo market report here:

https://www.thebusinessresearchcompany.com/report/adakveo-global-market-report

Which Geographic Regions Are Influencing Demand In The Adakveo Market?

North America was the largest region in the adakveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adakveo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Adakveo Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19955&type=smp

Browse Through More Reports Similar to the Global Adakveo Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Hypermarkets Market Report 2026

https://www.thebusinessresearchcompany.com/report/hypermarkets-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795